BioNTech SE BNTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -53.40% | -75.28% | -958.16% | 92.35% | -0.27% |
| Total Depreciation and Amortization | 118.07% | 472.83% | -126.22% | 150.86% | 28.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 62.75% | -108.80% | 2,013.70% | 212.88% | -309.02% |
| Change in Net Operating Assets | 791.81% | 129.26% | -135.16% | 27.65% | 231.23% |
| Cash from Operations | 102.48% | -236.72% | -60.53% | 448.95% | 120.24% |
| Capital Expenditure | 4.44% | 9.67% | -75.29% | -36.46% | 40.23% |
| Sale of Property, Plant, and Equipment | 111.24% | 168.00% | -79.40% | 497.43% | 7.85% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -101.80% | 192.89% | -226.71% | -2,331.68% | -102.97% |
| Cash from Investing | -103.75% | 197.74% | -193.30% | -1,380.08% | -105.57% |
| Total Debt Issued | -1.56% | 473.13% | -- | -- | -- |
| Total Debt Repaid | -42.50% | 36.84% | -65.22% | 13.53% | 3.62% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -508.55% | 285.55% | -23.81% | 10.93% | -3.94% |
| Foreign Exchange rate Adjustments | 3.51% | -344.09% | 106.48% | -340.74% | 161.63% |
| Miscellaneous Cash Flow Adjustments | -73.84% | -0.37% | 1,045.08% | -84.39% | 153.92% |
| Net Change in Cash | -108.71% | 194.13% | -1,263.04% | -315.03% | -78.43% |